Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Pancreatic Cancer
Asuragen Launches the First Validated microRNA Diagnostic Assay
May 6th, 2008
Asuragen, Inc. announced the launch of the first microRNA (miRNA) test for clinical diagnosis and disease management. The assay utilizes qRT-PCR technology* and differentiates between chronic pancreatitis and pancreatic cancer (pancreatic ductal adenocarcinoma). Pancreatic cancer is the 4th leading cause of cancer related deaths in the United States. Chronic pancreatitis and pancreatic cancer present similar symptoms and can be mis-diagnosed in up to 25% of patients. The test was developed following the discovery of novel microRNAs associated with pancreatic cancer in collaboration between Asuragen scientists and Dr. Stephan Hahn and colleagues at Ruhr University,...
Source: Cancer Weekly (2008-05-06)
|
